Savings associated with therapeutic appropriateness for patients with relapsed refractory multiple myeloma and high cytogenetic risk diagnosed by FISH test
DOI:
https://doi.org/10.33393/ao.2022.2447Keywords:
Appropriateness, Cost, FISH, HRC, Myeloma, TripletsAbstract
Background: Approximately 23% of myeloma patients have cytogenetic abnormalities which confer a significantly poorer prognosis, and therefore they are defined as “high-risk myeloma” (HRC+) patients.
Objective: To estimate the economic impact of a large-scale use of the fluorescence in situ hybridization (FISH) test for the identification of HRC+ patients.
Methods: The comparison between the total costs of two scenarios, the first one where patients are not tested for cytogenetic abnormalities, the second one where FISH test is used to identify HRC+ patients and to treat them with the most appropriate therapies, was conducted. The Italian National Healthcare Service (NHS) perspective was adopted. The cost of each treatment was estimated by multiplying Italian unit ex-factory prices by median progression-free survival (PFS). For each scenario, the cost per month of PFS gained was calculated. Sensitivity analysis was conducted to evaluate the impact on the results.
Results: N = 777 patients are expected to be HRC+ in Italy. If they were all identified through FISH test and treated with the most appropriate therapies, this would result into savings of € 552,000 and a PFS gain of 419 months, compared with a scenario with no identification. The cost per patient per month of PFS gained is lower in the scenario where FISH test was available (€ 9,921 vs € 10,229 in the scenario without testing). Sensitivity analyses confirmed the robustness of the base case results.
Conclusions: A larger adoption of FISH test to identify HRC+ patients is expected to improve clinical outcomes in relapsed refractory multiple myeloma.
Downloads
References
Offidani M, Boccadoro M, Di Raimondo F, Petrucci MT, Tosi P, Cavo M. Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. Curr Hematol Malig Rep. 2019;14(3):187-196. https://doi.org/10.1007/s11899-019-00507-x PMID:31077067 DOI: https://doi.org/10.1007/s11899-019-00507-x
Sistema nazionale linee guida dell’Istituto Superiore di Sanità. La terapia del Mieloma Multiplo: linee-guida della Società Italiana di Ematologia. 2021. Online https://snlg.iss.it/wp-content/uploads/2021/05/LG92_SIE_MM_v3.5.pdf (Accessed March 2022).
Scotti L, Montefusco V, Lanati EP, Orlando VL, Iorio A, Verdini V. Epidemiologia del mieloma multiplo e caratteristiche cliniche dei pazienti. G Ital di Farm e Farm. 2018;10:23-30 Online http://www.sefap.it/web/upload/GIFF2018-2_23_30.pdf (Accessed March 2022).
Corrao G, Montefusco V, De Solda F, et al. Rwd Study for Epidemiology and Characteristics of Patients with Multiple Myeloma in Italy. Blood. 2016;128(22):5693-5693. https://doi.org/10.1182/blood.V128.22.5693.5693 DOI: https://doi.org/10.1182/blood.V128.22.5693.5693
Mehta J, Harrison O, Barwood C, et al. PCN135 UTILITY VALUES IN PATIENTS WITH RR MULTIPLE MYELOMA - A SYSTEMATIC LITERATURE REVIEW. Value Health. 2020;23:S47. https://doi.org/10.1016/j.jval.2020.04.1624 DOI: https://doi.org/10.1016/j.jval.2020.04.1624
Benboubker L, Dimopoulos MA, Dispenzieri A, et al; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906-917. https://doi.org/10.1056/NEJMoa1402551 PMID:25184863 DOI: https://doi.org/10.1056/NEJMoa1402551
Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519-527. https://doi.org/10.1016/S0140-6736(16)31594-XPMID:28017406 DOI: https://doi.org/10.1016/S0140-6736(16)31594-X
Dimopoulos MA, Moreau P, Terpos E, et al; EHA Guidelines Committee. Electronic address: guidelines@ehaweb.org; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021;32(3):309-322. https://doi.org/10.1016/j.annonc.2020.11.014 PMID:33549387 DOI: https://doi.org/10.1016/j.annonc.2020.11.014
Lancman G, Tremblay D, Barley K, et al. The effect of novel therapies in high-molecular-risk multiple myeloma. Clin Adv Hematol Oncol. 2017;15(11):870-879. PMID:29200420
Legües ME, Morales P, Valenzuela M, et al. [High risk cytogenetic abnormalities in patients with multiple myeloma]. Rev Med Chil. 2019;147(1):61-64. PMID:30848766 DOI: https://doi.org/10.4067/S0034-98872019000100061
Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-2962. https://doi.org/10.1182/blood-2016-01-631200 PMID:27002115 DOI: https://doi.org/10.1182/blood-2016-01-631200
Avet-Loiseau H, Bahlis NJ, Chng WJ, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017;130(24):2610-2618. https://doi.org/10.1182/blood-2017-06-791228 PMID:29054911 DOI: https://doi.org/10.1182/blood-2017-06-791228
Agenzia Europea per i Medicinali (EMA). NINLARO (ixazomib) - riassunto delle caratteristiche del prodotto. Online https://www.ema.europa.eu/en/documents/product-information/ninlaro-epar-product-information_en.pdf (Accessed March 2022).
Agenzia Italiana del Farmaco (AIFA). Riclassificazione del medicinale per uso umano «Ninlaro» (Determina n. 283/2019) GU Serie Generale n.57 del 08-03-2019. Online https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2019-03-08&atto.codiceRedazionale=19A01444&elenco30giorni=false (A. confermare link)
Moreau P, Masszi T, Grzasko N, et al; TOURMALINE-MM1 Study Group. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;374(17):1621-1634. https://doi.org/10.1056/NEJMoa1516282 PMID:27119237 DOI: https://doi.org/10.1056/NEJMoa1516282
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford University Press; 2015:22.
Agenzia Italiana del Farmaco (AIFA). Linee guida per la compilazione del dossier a supporto della domanda di rimborsabilità e prezzo di un medicinale. Online https://www.aifa.gov.it/documents/20142/1283800/Linee_guida_dossier_domanda_rimborsabilita.pdf (Accessed August 2022).
Raab MS, Cavo M, Delforge M, et al. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016;175(1):66-76. https://doi.org/10.1111/bjh.14193 PMID:27291397 DOI: https://doi.org/10.1111/bjh.14193
IQVIA. Mieloma multiplo integrated tracking. Q3 2021. Data on file.
Lonial S, Dimopoulos M, Palumbo A, et al; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373(7):621-631. https://doi.org/10.1056/NEJMoa1505654 PMID:26035255 DOI: https://doi.org/10.1056/NEJMoa1505654
Stewart AK, Rajkumar SV, Dimopoulos MA, et al; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-152. https://doi.org/10.1056/NEJMoa1411321 PMID:25482145 DOI: https://doi.org/10.1056/NEJMoa1411321
Dimopoulos MA, Oriol A, Nahi H, et al; POLLUX Investigators. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(14):1319-1331. https://doi.org/10.1056/NEJMoa1607751 PMID:27705267 DOI: https://doi.org/10.1056/NEJMoa1607751
Palumbo A, Chanan-Khan A, Weisel K, et al; CASTOR Investigators. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(8):754-766. https://doi.org/10.1056/NEJMoa1606038 PMID:27557302 DOI: https://doi.org/10.1056/NEJMoa1606038
Richardson PG, Oriol A, Beksac M, et al; OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(6):781-794. https://doi.org/10.1016/S1470-2045(19)30152-4PMID:31097405
Agenzia Europea per i Medicinali (EMA). Kyprolis. Riassunto delle caratteristiche del prodotto. Online https://www.ema.europa.eu/en/documents/product-information/kyprolis-epar-product-information_en.pdf (Accessed March 2022).
Agenzia Europea per i Medicinali (EMA). Empliciti. Riassunto delle caratteristiche del prodotto. Online https://www.ema.europa.eu/en/documents/product-information/empliciti-epar-product-information_en.pdf (Accessed March 2022).
Agenzia Europea per i Medicinali (EMA). Darzalex. Riassunto delle caratteristiche del prodotto. Online https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf (Accessed March 2022).
Agenzia Europea per i Medicinali (EMA). Imnovid. RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO. Online https://www.ema.europa.eu/en/documents/product-information/imnovid-epar-product-information_en.pdf (Accessed March 2022).
Agenzia Italiana del Farmaco (AIFA). Lista dei farmaci in classe A. Online https://www.aifa.gov.it/liste-farmaci-a-h (Accessed March 2022).
Ministero della salute. Tariffe delle prestazioni ambulatoriali. Supplemento n.8, Gazzetta Ufficiale n. 23, 2013. Allegato 3 Online https://www.gazzettaufficiale.it/eli/gu/2013/01/28/23/so/8/sg/pdf (Accessed October 2022)
Bollettino d’Informazione Farmaco Economica (BIFE). Il test FISH nel mieloma multiplo: mappatura dei laboratori che effettuano il test in italia. Numero monografico speciale. Dicembre 2021. Online http://www.e-communications.it/Mated.IQVIA/BIFE/Pdf/Bife_Fish_Test.pdf
Ripellino C, Pegoraro V, Heiman F. Cost-offsets in relapsed/refractory multiple myeloma and resource consumption derived from Italian real practice. Clin Outcomes Res. 2019;14:55-64. Online http://www.clinicoeconomics.eu/articles/flipbook/files/downloads/14_2019_55-64.pdf
Istituto nazionale di statistica (ISTAT). Rivalutazioni e documentazione su prezzi, costi e retribuzioni contrattuali. Online https://rivaluta.istat.it/ (Accessed October 2022).
Poggio F, Tagliamento M, Di Maio M, et al. Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities. JCO Oncol Pract. 2020;16(11):e1304-e1314. https://doi.org/10.1200/OP.20.00297 PMID:32574131 DOI: https://doi.org/10.1200/OP.20.00297
Viale G, Licata L, Sica L, et al. Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak. Oncologist. 2020;25(7):e1013-e1020. https://doi.org/10.1634/theoncologist.2020-0316 PMID:32412693 DOI: https://doi.org/10.1634/theoncologist.2020-0316
Valenza F, Papagni G, Marchianò A, et al. Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS-Istituto Nazionale dei Tumori di Milano. Tumori. 2020;106(3):300891620923790. https://doi.org/10.1177/0300891620923790 PMID:32364028 DOI: https://doi.org/10.1177/0300891620923790
Quaquarini E, Saltalamacchia G, Presti D, et al. Impact of COVID-19 Outbreak on Cancer Patient Care and Treatment: Data from an Outpatient Oncology Clinic in Lombardy (Italy). Cancers (Basel). 2020;12(10):1-16. https://doi.org/10.3390/cancers12102941 PMID:33053782 DOI: https://doi.org/10.3390/cancers12102941
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Rossella Bitonti, Federica Demma, Massimiliano Rea, Gianluca Furneri
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2022-10-25
Published 2022-11-24
